CA2859203C - Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone - Google Patents

Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone Download PDF

Info

Publication number
CA2859203C
CA2859203C CA2859203A CA2859203A CA2859203C CA 2859203 C CA2859203 C CA 2859203C CA 2859203 A CA2859203 A CA 2859203A CA 2859203 A CA2859203 A CA 2859203A CA 2859203 C CA2859203 C CA 2859203C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
methylnaltrexone
subject
use according
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2859203A
Other languages
English (en)
French (fr)
Other versions
CA2859203A1 (en
Inventor
Enoch Bortey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Inc
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Publication of CA2859203A1 publication Critical patent/CA2859203A1/en
Application granted granted Critical
Publication of CA2859203C publication Critical patent/CA2859203C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2859203A 2011-12-19 2012-12-19 Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone Active CA2859203C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577654P 2011-12-19 2011-12-19
US61/577,654 2011-12-19
PCT/US2012/070612 WO2013096444A1 (en) 2011-12-19 2012-12-19 Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone

Publications (2)

Publication Number Publication Date
CA2859203A1 CA2859203A1 (en) 2013-06-27
CA2859203C true CA2859203C (en) 2020-08-25

Family

ID=48669445

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859203A Active CA2859203C (en) 2011-12-19 2012-12-19 Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone

Country Status (11)

Country Link
US (2) US20130317050A1 (enExample)
EP (1) EP2793888A4 (enExample)
JP (2) JP2015501849A (enExample)
KR (1) KR20140107540A (enExample)
CN (2) CN110384701A (enExample)
AU (3) AU2012359013A1 (enExample)
BR (1) BR112014014805A2 (enExample)
CA (1) CA2859203C (enExample)
IL (1) IL233266A0 (enExample)
MX (1) MX2014007312A (enExample)
WO (1) WO2013096444A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
EP3206491B1 (en) * 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
JP2019513355A (ja) * 2016-03-29 2019-05-30 コロナリーコンセプツ エルエルシー 便秘症を処置するための製剤
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
WO2003086415A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
SE0303135D0 (sv) * 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
EP1906951A4 (en) * 2005-07-01 2009-05-27 Dynogen Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL HYPOMOTILITY AND RELEVANT DISEASES
CN102014907A (zh) * 2008-05-07 2011-04-13 尼克塔治疗公司 外周作用阿片拮抗剂的口服给药
CN101845047B (zh) * 2009-12-31 2011-12-07 南京臣功制药有限公司 一种溴甲基纳曲酮的制备方法
TWI605814B (zh) * 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽

Also Published As

Publication number Publication date
IL233266A0 (en) 2014-08-31
CA2859203A1 (en) 2013-06-27
US20190231771A1 (en) 2019-08-01
AU2012359013A1 (en) 2014-06-26
WO2013096444A1 (en) 2013-06-27
JP2019048820A (ja) 2019-03-28
EP2793888A4 (en) 2015-10-28
JP2015501849A (ja) 2015-01-19
US20130317050A1 (en) 2013-11-28
MX2014007312A (es) 2014-08-27
CN110384701A (zh) 2019-10-29
EP2793888A1 (en) 2014-10-29
BR112014014805A2 (pt) 2017-06-13
CN104254332A (zh) 2014-12-31
NZ625863A (en) 2016-11-25
AU2017258808A1 (en) 2017-11-23
KR20140107540A (ko) 2014-09-04
AU2019203694A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
US10307417B2 (en) Oral formulations and lipophilic salts of methylnaltrexone
AU2009201019B2 (en) Dosage form containing oxycodone and naloxone
US20190231771A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
KR101971412B1 (ko) 정맥 내 투여용 이부프로펜의 투여
KR20250145673A (ko) 통증 완화에 유용한 요법 및 조성물
NZ625863B2 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) Methods of administering methylnaltrexone
AU2013203559B2 (en) Oral formulations and lipophilic salts of methylnaltrexone
AU2016200133B2 (en) Oral formulations and lipophilic salts of methylnaltrexone
BR102013032395A2 (pt) Composição farmacêutica oral estável
BR102014003686A2 (pt) composição farmacêutica oral estável
HK1158534B (en) Oral formulations and lipophilic salts of methylnaltrexone
HK1158534A (en) Oral formulations and lipophilic salts of methylnaltrexone

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170804

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121